Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Published: May 05, 2021
WATERTOWN, Mass., May 05, 2021 (GLOBE NEWSWIRE) Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Juliet Williams, PhD, as Senior Vice President, Head of Biology. Dr. Williams joins Kymera with 20 years of experience in the biopharmaceutical industry, including leadership roles in drug discovery and translational development.
“I’m very excited to welcome Juliet to the leadership team at Kymera,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “Juliet has been a successful drug hunter in both biotech and large pharma. Her expertise and leadership in target identification, drug discovery, and translational drug development across small molecule and innovative drug classes will be invaluable as we continue to expand Kymera’s capabilities to build a
Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.